Invention Grant
- Patent Title: Dextran sulfate
-
Application No.: US16520930Application Date: 2019-07-24
-
Publication No.: US10730960B2Publication Date: 2020-08-04
- Inventor: Lars Bruce , Ulf Brasen
- Applicant: TX Medic AB
- Applicant Address: SE Viken
- Assignee: TX MEDIC AB
- Current Assignee: TX MEDIC AB
- Current Assignee Address: SE Viken
- Agency: Porter Wright Morris & Arthur LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@3263f0d6
- Main IPC: C08B37/02
- IPC: C08B37/02 ; A61P29/00 ; C08L5/02

Abstract:
Methods of treating, inhibiting and/or preventing instant blood-mediated inflammatory reaction (IBMIR) comprise administering, to a subject, a dextran sulfate characterized by a number average molecular weight (Mn) as measured by nuclear magnetic resonance (NMR) spectroscopy within an interval of 1850 and 3500 Da; an average sulfate number per glucose unit within an interval of 2.5 and 3.0; and an average sulfation of C2 position in the glucose units of said dextran sulfate of at least 90%, or a salt of such a dextran sulfate.
Public/Granted literature
- US20190375859A1 DEXTRAN SULFATE Public/Granted day:2019-12-12
Information query